Abstract Number: 0452 • ACR Convergence 2020
Recombinant Zoster Vaccine in Patients with Rheumatic Diseases: A Retrospective Study of 622 Patients
Background/Purpose: The recombinant herpes zoster vaccine (RZV) was FDA-approved in 2017 but patients with rheumatic diseases were excluded from initial pivotal trials because of theoretical…Abstract Number: 0465 • ACR Convergence 2020
The COVID-19 Pandemic and Its Effect on Patients with Chronic Rheumatologic Disease Regarding the Value of Vaccination Recommendations
Background/Purpose: Vaccinations are an important component of care in rheumatology as many patients are immunocompromised by treatment therapies. Patients are sometimes reticent to receive recommended…Abstract Number: 0541 • ACR Convergence 2020
Suboptimal Vaccination Coverage with Influenza, Pneumococcal and Herpes Zoster Vaccines Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases in a Nationwide Health Care Plan
Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIIRD) increase the susceptibility to infections. Immunisation against vaccine-preventable diseases is recommended for patients with AIIRD by most international medical…Abstract Number: 0598 • ACR Convergence 2020
Impact of a Dedicated Lupus Nephritis Clinic to Improve Time to Biopsy and Care Quality
Background/Purpose: Lupus nephritis (LN) contributes to a 10-fold higher risk to develop kidney failure and 26-fold higher mortality compared to peers. Kidney biopsy remains a…Abstract Number: 1199 • 2019 ACR/ARP Annual Meeting
Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus
Background/Purpose: Patients with lupus have higher rates of cervical dysplasia and pre-malignant cervical lesions. At our institution, an urban referral center for patients with lupus, rates…Abstract Number: 1749 • 2019 ACR/ARP Annual Meeting
Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used in the treatment of autoimmune diseases. However, its use is associated with progressive irreversible retinal damage and vision loss…Abstract Number: 2105 • 2019 ACR/ARP Annual Meeting
The Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids
Background/Purpose: Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended as a first-line agent of pneumocystis pneumonia (PCP) prophylaxis for those who receive prolonged high-dose glucocorticoids. Alternative agents can be…Abstract Number: 2268 • 2019 ACR/ARP Annual Meeting
Preferences and Insights for Rheumatoid Arthritis Clinical Prevention Trial Participation
Background/Purpose: In rheumatoid arthritis (RA) development, autoantibodies to citrullinated protein antigens (ACPA) are elevated in the blood before clinically-apparent synovitis develops. These findings underpin the…Abstract Number: 1235 • 2018 ACR/ARHP Annual Meeting
Isoniazid Monotherapy As a Prophylaxis for Tuberculosis in Patients with Rheumatic Diseases Exposed to Prolonged, High-Dose Glucocorticoids
Background/Purpose: Although use of glucocorticoid increases the risk of tuberculosis (TB) disease, there has been few studies investigating its incidence and risk/benefit assessment of the…Abstract Number: 1596 • 2018 ACR/ARHP Annual Meeting
Atherosclerotic Cardiovascular Disease in Psoriatic Arthritis: Evaluation of Risk Factor Management and Use of Aspirin and Statin for Prevention in a Primary Care Setting
Background/Purpose: There is accumulating evidence that shows an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) risk factors among the psoriatic arthritis (PsA) population. The aim…Abstract Number: 1642 • 2018 ACR/ARHP Annual Meeting
Systematic Screening of Comorbidities Improves Vaccination Rates, Skin Cancer Screening and Vitamin D Supplementation in Patients with Axial Spondyloarthritis: Results of a Prospective, Controlled ,One Year Randomised Trial
Background/Purpose: Specific recommendations for the detection/prevention of comorbidities have been proposed for patients with SpA. However, we know that often a gap exists between recommendation…Abstract Number: 1909 • 2018 ACR/ARHP Annual Meeting
Impact and Timing of Smoking Cessation on Reducing Risk for Seropositive Rheumatoid Arthritis Among Women
Background/Purpose: Compared to never smoking, past and current smoking are both associated with increased risk of seropositive rheumatoid arthritis (RA). Thus, smoking cessation may delay…Abstract Number: 295 • 2018 ACR/ARHP Annual Meeting
Implementing a Staff Tobacco Cessation Protocol Increases Quit Line Referrals in a Community Rheumatology Practice
Background/Purpose: Smoking remains the leading preventable cause of US mortality and predicts higher incidence, greater severity, and reduced treatment response in many rheumatologic conditions. Despite…Abstract Number: 344 • 2018 ACR/ARHP Annual Meeting
Use of Lean Six-Sigma Methodologies to Improve Pneumococcal Vaccination Rates Among Immunocompromised Veterans with Rheumatologic Diseases: A Quality Improvement Project
Background/Purpose: Pneumonia is a leading cause of morbidity and mortality in the United States among immunocompromised individuals with rheumatologic diseases. Despite the publication of Advisory…Abstract Number: 841 • 2017 ACR/ARHP Annual Meeting
Optimal Regimens of Sulfamethoxazole-Trimethoprim for Chemoprophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Diseases: 52-Week Follow-up of a Non-Blinded, Randomized Controlled Trial
Background/Purpose: Sulfamethoxazole-trimethoprim (SMX/TMP) is a standard drug for the prophylaxis of Pneumocystis pneumonia (PCP), but is sometimes discontinued due to adverse events (AEs). We have…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- Next Page »